|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 30216 |
FusionGeneSummary for RAF1_EIF3L |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: RAF1_EIF3L | Fusion gene ID: 30216 | Hgene | Tgene | Gene symbol | RAF1 | EIF3L | Gene ID | 5894 | 51386 |
| Gene name | Raf-1 proto-oncogene, serine/threonine kinase | eukaryotic translation initiation factor 3 subunit L | |
| Synonyms | CMD1NN|CRAF|NS5|Raf-1|c-Raf | EIF3EIP|EIF3S11|EIF3S6IP|HSPC021|HSPC025|MSTP005 | |
| Cytomap | 3p25.2 | 22q13.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | RAF proto-oncogene serine/threonine-protein kinaseC-Raf proto-oncogene, serine/threonine kinaseOncogene RAF1proto-oncogene c-RAFraf proto-oncogene serine/threonine protein kinasev-raf-1 murine leukemia viral oncogene homolog 1v-raf-1 murine leukemia | eukaryotic translation initiation factor 3 subunit LeIEF associated protein HSPC021eukaryotic translation initiation factor 3 subunit 6-interacting proteineukaryotic translation initiation factor 3 subunit E-interacting protein | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P04049 | Q9Y262 | |
| Ensembl transtripts involved in fusion gene | ENST00000251849, ENST00000442415, ENST00000534997, ENST00000542177, | ENST00000412331, ENST00000381683, ENST00000406934, ENST00000476955, | |
| Fusion gene scores | * DoF score | 13 X 7 X 14=1274 | 7 X 8 X 6=336 |
| # samples | 27 | 9 | |
| ** MAII score | log2(27/1274*10)=-2.23833396520547 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/336*10)=-1.90046432644909 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: RAF1 [Title/Abstract] AND EIF3L [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Oncogene involved fusion gene, in-frame and retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RAF1 | GO:0000186 | activation of MAPKK activity | 10644344 |
| Hgene | RAF1 | GO:0007190 | activation of adenylate cyclase activity | 15385642 |
| Hgene | RAF1 | GO:0008285 | negative regulation of cell proliferation | 9765203 |
| Hgene | RAF1 | GO:0031333 | negative regulation of protein complex assembly | 19667065 |
| Hgene | RAF1 | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
| Hgene | RAF1 | GO:0043066 | negative regulation of apoptotic process | 19667065 |
| Tgene | EIF3L | GO:0006413 | translational initiation | 17581632 |
| Tgene | EIF3L | GO:0075525 | viral translational termination-reinitiation | 21347434 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | DLBC | TCGA-G8-6325-01A | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000251849 | ENST00000412331 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| In-frame | ENST00000251849 | ENST00000381683 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| In-frame | ENST00000251849 | ENST00000406934 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| 5CDS-intron | ENST00000251849 | ENST00000476955 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| In-frame | ENST00000442415 | ENST00000412331 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| In-frame | ENST00000442415 | ENST00000381683 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| In-frame | ENST00000442415 | ENST00000406934 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| 5CDS-intron | ENST00000442415 | ENST00000476955 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000534997 | ENST00000412331 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000534997 | ENST00000381683 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000534997 | ENST00000406934 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-intron | ENST00000534997 | ENST00000476955 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000542177 | ENST00000412331 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000542177 | ENST00000381683 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-3CDS | ENST00000542177 | ENST00000406934 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
| intron-intron | ENST00000542177 | ENST00000476955 | RAF1 | chr3 | 12653449 | - | EIF3L | chr22 | 38282772 | + |
Top |
FusionProtFeatures for RAF1_EIF3L |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RAF1 | EIF3L |
| Serine/threonine-protein kinase that acts as aregulatory link between the membrane-associated Ras GTPases andthe MAPK/ERK cascade, and this critical regulatory link functionsas a switch determining cell fate decisions includingproliferation, differentiation, apoptosis, survival and oncogenictransformation. RAF1 activation initiates a mitogen-activatedprotein kinase (MAPK) cascade that comprises a sequentialphosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 andMAP2K2/MEK2) and the extracellular signal-regulated kinases(MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (onresidues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylylcyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.Phosphorylates PPP1R12A resulting in inhibition of the phosphataseactivity. Phosphorylates TNNT2/cardiac muscle troponin T. Canpromote NF-kB activation and inhibit signal transducers involvedin motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2),proliferation and angiogenesis (RB1). Can protect cells fromapoptosis also by translocating to the mitochondria where it bindsBCL2 and displaces BAD/Bcl2-antagonist of cell death. RegulatesRho signaling and migration, and is required for normal woundhealing. Plays a role in the oncogenic transformation ofepithelial cells via repression of the TJ protein, occludin (OCLN)by inducing the up-regulation of a transcriptional repressorSNAI2/SLUG, which induces down-regulation of OCLN. Restrictscaspase activation in response to selected stimuli, notably Fasstimulation, pathogen-mediated macrophage apoptosis, and erythroiddifferentiation. {ECO:0000269|PubMed:11427728,ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,ECO:0000269|PubMed:9360956}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000251849 | - | 3 | 17 | 349_609 | 106 | 649 | Domain | Protein kinase |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000251849 | - | 3 | 17 | 56_131 | 106 | 649 | Domain | RBD |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000442415 | - | 3 | 18 | 349_609 | 106 | 669 | Domain | Protein kinase |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000442415 | - | 3 | 18 | 56_131 | 106 | 669 | Domain | RBD |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000251849 | - | 3 | 17 | 355_363 | 106 | 649 | Nucleotide binding | ATP |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000442415 | - | 3 | 18 | 355_363 | 106 | 669 | Nucleotide binding | ATP |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000251849 | - | 3 | 17 | 138_184 | 106 | 649 | Zinc finger | Phorbol-ester/DAG-type |
| Hgene | >RAF1 | chr3:12653449 | chr22:38282772 | ENST00000442415 | - | 3 | 18 | 138_184 | 106 | 669 | Zinc finger | Phorbol-ester/DAG-type |
| Tgene | EIF3L | chr3:12653449 | chr22:38282772 | ENST00000381683 | + | 8 | 11 | 331_537 | 477 | 517 | Domain | PCI |
| Tgene | EIF3L | chr3:12653449 | chr22:38282772 | ENST00000412331 | + | 10 | 13 | 331_537 | 525 | 565 | Domain | PCI |
Top |
FusionGeneSequence for RAF1_EIF3L |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_146aa MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRG |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_440nt ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCT ACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGC CTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTT |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_1823nt AGTCGACTGCCAGTAGGGCTCGCGCAGAATCGGAGAGCCGGTGGCGTCGCAGGTCGGGAGGACGAGCACCGAGTCGAGGGCTCGCTCGTC TGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGAGGCGGGAACGGC TTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCGTTTGCTACGATG CGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCGGGGAGGAGGAGC GGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACA TACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCTACAATAGTTC AGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTTTTCTTGCCGA ACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGCCTGCAACCAG AGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTTATGGGGATTT CTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATCGAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTCACACACATTCAG GAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTTGCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGTCAACTCAGTTAA CAAGTTAAGGACCGAAGTGTTTCAAGTGGATCTCAGTAAAGGATCTTTGGAGCCAGATTTGTCGTCTCATTATTGTAGGAGAGAATTTGT GGGTTGTGGCAGTAATACATTTCCCATGTGTCCTGATGCTTTCAGGATACATCAGTTGTTAGTGTTTAAATTGAGTTATTTTTATTTTGT GCTTTTGAGATGGAGTCTCACTCTGTCTCCCAGGCTGGAGTGCAGTAGCGTGATCTCAGTTCGTTGCATCCTCCGCTGCCCAGGTTCAAG CAGTTCTGCCTCAGCCTTCCAAGTAGCTGGGATTACAGGCGTGTGCCACCACACTCAGCTAATTTTTGTATTCTCAGTAGAGATGGGTTT TACCATGTTGGCCAGGCTGGTCTCGAACTCCTGGCCTCAAGTGATTCGCCTGCCTTGGCCTCCCAAAATGTGCTAGGATTACAGGCATGA GCCACCACGCCCCGCCTAAATTCAAAATCTTTTTGTTTTTTTTTAGACGGAGTCTCACTCTGTCGCCCAGGTTGGAGTGTACTGGCGCGA TCTCGGCTCACTGCAAGCTCCACCTCCCAGGTTCCTGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACCCGCCACC ATGCCCGGCCAATTTTTTGTATTTTTTAGTAGAGATGGGGTTTCACCGTGTTAGCCAGGATGGTCTCAGATTTCCTGACCTCGTGATCTG CCCATCTCTGCCTCCTAAAGTACTGGGATTACAGGCGTGAGCCACCGTGCCCAGCCCTAAATTGAATTCTTAAATCCCTCTTGTTCATAA >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_895nt AGTCGACTGCCAGTAGGGCTCGCGCAGAATCGGAGAGCCGGTGGCGTCGCAGGTCGGGAGGACGAGCACCGAGTCGAGGGCTCGCTCGTC TGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGAGGCGGGAACGGC TTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCGTTTGCTACGATG CGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCGGGGAGGAGGAGC GGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACA TACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCTACAATAGTTC AGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTTTTCTTGCCGA ACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGCCTGCAACCAG AGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTTATGGGGATTT >In-frame_RAF1_ENST00000251849_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_1046nt AGTCGACTGCCAGTAGGGCTCGCGCAGAATCGGAGAGCCGGTGGCGTCGCAGGTCGGGAGGACGAGCACCGAGTCGAGGGCTCGCTCGTC TGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGAGGCGGGAACGGC TTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCGTTTGCTACGATG CGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCGGGGAGGAGGAGC GGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACA TACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCTACAATAGTTC AGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTTTTCTTGCCGA ACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGCCTGCAACCAG AGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTTATGGGGATTT CTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATCGAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTCACACACATTCAG GAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTTGCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGTCAACTCAGTTAA >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000412331_chr22_38282772_+_1745nt GGCTCGCTCGTCTGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGA GGCGGGAACGGCTTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCG TTTGCTACGATGCGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCG GGGAGGAGGAGCGGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCAT CAATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTC CTACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTG TTTTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGG GCCTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCG TTATGGGGATTTCTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATCGAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTC ACACACATTCAGGAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTTGCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGT CAACTCAGTTAACAAGTTAAGGACCGAAGTGTTTCAAGTGGATCTCAGTAAAGGATCTTTGGAGCCAGATTTGTCGTCTCATTATTGTAG GAGAGAATTTGTGGGTTGTGGCAGTAATACATTTCCCATGTGTCCTGATGCTTTCAGGATACATCAGTTGTTAGTGTTTAAATTGAGTTA TTTTTATTTTGTGCTTTTGAGATGGAGTCTCACTCTGTCTCCCAGGCTGGAGTGCAGTAGCGTGATCTCAGTTCGTTGCATCCTCCGCTG CCCAGGTTCAAGCAGTTCTGCCTCAGCCTTCCAAGTAGCTGGGATTACAGGCGTGTGCCACCACACTCAGCTAATTTTTGTATTCTCAGT AGAGATGGGTTTTACCATGTTGGCCAGGCTGGTCTCGAACTCCTGGCCTCAAGTGATTCGCCTGCCTTGGCCTCCCAAAATGTGCTAGGA TTACAGGCATGAGCCACCACGCCCCGCCTAAATTCAAAATCTTTTTGTTTTTTTTTAGACGGAGTCTCACTCTGTCGCCCAGGTTGGAGT GTACTGGCGCGATCTCGGCTCACTGCAAGCTCCACCTCCCAGGTTCCTGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAG GCACCCGCCACCATGCCCGGCCAATTTTTTGTATTTTTTAGTAGAGATGGGGTTTCACCGTGTTAGCCAGGATGGTCTCAGATTTCCTGA CCTCGTGATCTGCCCATCTCTGCCTCCTAAAGTACTGGGATTACAGGCGTGAGCCACCGTGCCCAGCCCTAAATTGAATTCTTAAATCCC >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000381683_chr22_38282772_+_817nt GGCTCGCTCGTCTGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGA GGCGGGAACGGCTTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCG TTTGCTACGATGCGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCG GGGAGGAGGAGCGGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCAT CAATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTC CTACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTG TTTTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGG GCCTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCG TTATGGGGATTTCTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATCGAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTC >In-frame_RAF1_ENST00000442415_chr3_12653449_-_EIF3L_ENST00000406934_chr22_38282772_+_968nt GGCTCGCTCGTCTGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGA GGCGGGAACGGCTTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCG TTTGCTACGATGCGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCG GGGAGGAGGAGCGGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCAT CAATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTC CTACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTG TTTTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGG GCCTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCG TTATGGGGATTTCTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATCGAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTC ACACACATTCAGGAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTTGCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGT |
Top |
FusionGenePPI for RAF1_EIF3L |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| RAF1 | YWHAQ, YWHAG, YWHAZ, SFN, HRAS, VDAC1, PEBP4, CNKSR1, RASD2, CNKSR2, ERAS, SPRY4, SPRY2, YWHAB, OIP5, PHKA2, CCT3, MYC, AR, MRAS, KRAS, LRPAP1, RRAS2, SHOC2, TSC22D3, STK26, MAPK1, MAPK3, PRKCE, BCL2, BCL2L1, PEBP1, MAP2K1, GRB10, NRAS, MAPK8IP3, AKT1, HSP90AA1, GNG4, GNB2, VAV1, RHEB, RAP1A, SRC, FYN, RB1, RBL2, PRKG1, JAK2, YWHAH, CFLAR, CDC25A, BRAF, MAP3K1, PDGFRB, MAP3K5, MAPK7, PHB, BAG1, PAK1, PRKCZ, RRAS, PRPF6, UBE2D2, YWHAE, NR3C1, LCK, LTK, JAK1, XIAP, BIRC2, BIRC3, STUB1, EEF1A1, HSPA8, HSPA5, CALM1, SGK1, NEDD4, SCNN1B, NEDD4L, STK3, BRAP, WDR83, KSR1, LATS1, MAP2K2, RFXANK, PPP1CC, VCP, HSPD1, BAD, BCL6, BIRC7, PIN1, MMS19, PPP2R1A, PPP2R2B, PPP2CA, HSPA4, RAF1, PPP2CB, MAPK8, RBBP8, YY1, PKM, CDK20, HIPK4, TBXA2R, SH3KBP1, ILK, GPRASP2, CDC37, IRS4, FAM96B, HUWE1, RANBP9, TMEM70, PACSIN3, NPLOC4, PRKAR1A, DCAF8, PURA, FYCO1, MYBPC1, COPS7A, MOV10, NXF1, EGFR, CALU, CCT8, DNAJA1, EMD, TIMM50, LOX, ARRB2, AGTR1, CASZ1, MRC2, PDLIM2, HERC2, XPO1, ACOX1, PCDH7, MAD2L1, SYNPO, TMEM63B, EEF1E1, COPS5, SS18L2, NUP133, RPGRIP1L, NCAPG2, NUP107, MSH2, LAS1L, AMER1, NUP160, EIF3D, SPATA7, NPHP4, DYNLL2, DYNLL1, IQCB1, RMDN3, TRIM25 | EIF3L | EIF3K, EIF3A, EIF1B, EIF4A2, EIF3D, EIF3E, EIF3H, EIF3F, H2AFX, TADA2A, AGO3, HDAC5, EIF3B, RGS2, SIRT7, CUL1, EIF3C, EIF3G, EIF3M, EIF3I, NCL, FN1, VCAM1, SMAD2, ITGA4, RRN3, CD81, IGSF8, ICAM1, XRN2, DDX3X, KCMF1, LARP1, RPS13, RPS16, RPS18, RPS20, RPS25, RPS28, RPS4X, RPS5, RPS8, RPS9, RIOK2, RNF2, EIF3CL, EIF2B5, NUMA1, NTRK1, HERC2, XPO1, AHSA1, NPM1, RPL10, CEP170P1, GAN, MCM2, C1orf131, ZNF746, PRRC2B, PSMD12, GNB2, PTP4A1, TTC21B, CYLD, G3BP1, BRCA1, YAP1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Hgene | RAF1 | chr3:12653449 | chr22:38282772 | ENST00000251849 | - | 3 | 17 | 331_349 | 106 | 649 | PEBP1/RKIP |
| Hgene | RAF1 | chr3:12653449 | chr22:38282772 | ENST00000442415 | - | 3 | 18 | 331_349 | 106 | 669 | PEBP1/RKIP |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for RAF1_EIF3L |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | RAF1 | P04049 | DB08896 | Regorafenib | RAF proto-oncogene serine/threonine-protein kinase | small molecule | approved |
| Hgene | RAF1 | P04049 | DB00398 | Sorafenib | RAF proto-oncogene serine/threonine-protein kinase | small molecule | approved|investigational |
| Hgene | RAF1 | P04049 | DB08862 | Cholecystokinin | RAF proto-oncogene serine/threonine-protein kinase | small molecule | approved|investigational |
| Hgene | RAF1 | P04049 | DB08912 | Dabrafenib | RAF proto-oncogene serine/threonine-protein kinase | small molecule | approved|investigational |
Top |
RelatedDiseases for RAF1_EIF3L |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RAF1 | C1969057 | Noonan Syndrome 5 | 3 | CTD_human;UNIPROT |
| Hgene | RAF1 | C0007194 | Hypertrophic Cardiomyopathy | 2 | CTD_human;HPO |
| Hgene | RAF1 | C0028326 | Noonan Syndrome | 2 | CTD_human;ORPHANET |
| Hgene | RAF1 | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| Hgene | RAF1 | C0007193 | Cardiomyopathy, Dilated | 1 | CTD_human;HPO |
| Hgene | RAF1 | C0017638 | Glioma | 1 | CTD_human |
| Hgene | RAF1 | C0020429 | Hyperalgesia | 1 | CTD_human |
| Hgene | RAF1 | C0022665 | Kidney Neoplasm | 1 | CTD_human |
| Hgene | RAF1 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Hgene | RAF1 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Hgene | RAF1 | C0175704 | LEOPARD Syndrome | 1 | CTD_human;ORPHANET |
| Hgene | RAF1 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
| Hgene | RAF1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Hgene | RAF1 | C4014656 | CARDIOMYOPATHY, DILATED, 1NN | 1 | UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|